We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
INTRAVENOUS LEVETIRACETAM AS SECOND LINE OPTION FOR STATUS EPILEPTICUS.
- Authors
UNGUREANU, AURELIAN; RUS, LUCA LIVIU; GLIGOR, FELICIA GABRIELA; LĂZĂROAE, ANA; PRODAN, LIIANA; ROMAN-FILIP, CORINA
- Abstract
Status epilepticus (SE) and seizure clusters (SC) are life-threatening acute neurologic disorders and represent medical emergencies, requiring rapid and effective treatment. We studied retrospectively 67 patients admitted in our Neurological Intensive Care Unit, with SE or SC between December 2011 and January 2016 and we analysed the efficacy and tolerability of intravenous (IV) administration of levetiracetam (LEV) for SE and SC. The indications for IV LEV as second line treatment were SE or SC unresponsive to IV diazepam and the presence of co-morbidities that made phenytoin administration unsafe. IV LEV was administered as second line therapy immediately after no response from 10 mg of IV diazepam, in a maximum dose of 3000 mg/day. Unresponsive patients or patients at risk required general anaesthesia. The cessation of seizures within 3 hours, relations between variables and adverse events were evaluated. In 86.9% of the cases (58 patients), SE stopped within 3 h. Our study showed that IV LEV is an effective treatment for refractory SE or SC of different etiology.
- Subjects
STATUS epilepticus treatment; ANTICONVULSANTS; INTRAVENOUS therapy; SPASM treatment; GENERAL anesthesia
- Publication
Farmacia, 2016, Vol 64, Issue 4, p507
- ISSN
0014-8237
- Publication type
Article